Compare Shell PLC (SHEL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs BIO-TECHNE Corp — how do they compare? Shell PLC trades at $99.1 (market cap $275.54B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Shell PLC is far larger — about 24.2× BIO-TECHNE Corp's market cap, and Shell PLC pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Shell PLC for 90 Days and BIO-TECHNE Corp for 63 Days on average.
| SHEL | TECH | |
|---|---|---|
Market Cap | $275.54B | $11.37B |
Volume | 4,925,662 | 3,153,511 |
Sector | Energy | Health |
52-Week High | $100.20 | $72.61 |
52-Week Low | $70.31 | $43.31 |
Typical Hold Time | 90 Days | 63 Days |
Enterprise Value | $317.24B | $11.40B |
Dividend Yield | 3.23% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $100.20, up 2.64% today, approaching its 52-week high with strong technical momentum. The stock shows solid fundamentals with a P/E of 10.71 and net income margin of 8.76%, supported by recent earnings beats. Recent developments include the LNG Canada Phase 2 expansion approval, doubling export capacity to 28 million metric tons annually, positioning Shell for long-term growth in global LNG markets.
Outlook remains positive with analyst consensus at Buy (61.5%) and $102.53 price target. Key opportunities include LNG expansion and portfolio optimization, while risks involve energy price volatility and execution of major projects. The current valuation appears reasonable given strong cash flow generation and strategic positioning in transitional energy markets.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
